Q3 FY2026 · ended Sep 27, 2026 · Revenue $618.90M, -11.6% YoY · Filed Nov 4, 2026
Quidelortho Corp (QDEL) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q3 of fiscal 2026, the quarter ended Sep 27, 2026, it reported revenue of $618.9 million and a net loss of $53.8 million. Free cash flow was -$1.4 million. As of Sep 27, 2026 it held $166.4 million in cash and investments and $603.4 million in total debt.
Revenue
$618.90M
-11.6% vs year-ago quarter
Net income
$-53.80M
+92.7% vs year-ago quarter
Operating cash flow
$19.60M
+143.1% vs year-ago quarter
Free cash flow
$-1.40M
+98.5% vs year-ago quarter
EPS
$-0.78
+92.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
68.61M
+1.0% vs year-ago quarter
Net cash
$-437.00M
Q3 FY2026
Operating margin
-4.9%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QDEL (Nasdaq)
- Fiscal year ends
- January 1
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1906324
- Former names
- Coronado Topco, Inc. (until Apr 11, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 27, 2026 |
Q2 FY2026 Jun 28, 2026 |
Q1 FY2026 Mar 29, 2026 |
Q4 FY2025 Dec 28, 2025 |
Q3 FY2025 Sep 28, 2025 |
|---|---|---|---|---|---|
| Revenue | $618.9M | $630.9M | $619.8M | $723.6M | $699.9M |
| Operating income | -$7.5M | -$21.8M | -$31.8M | -$66.3M | -$704.8M |
| Net income | -$53.8M | -$92.9M | -$91.8M | -$130.7M | -$733.0M |
| Diluted EPS | -$0.78 | -$1.36 | -$1.35 | -$1.92 | -$10.78 |
| Operating cash flow | $19.6M | -$110.6M | -$33.0M | $131.9M | -$45.5M |
| Free cash flow | -$1.4M | -$136.1M | -$67.0M | $87.4M | -$95.5M |
| Total assets | $5.8B | $5.7B | $5.6B | $5.8B | $5.7B |
| Total liabilities | $4.0B | $3.9B | $3.8B | $3.8B | $3.6B |
| Stockholders' equity | $1.8B | $1.8B | $1.9B | $1.9B | $2.0B |
| Cash and investments | $166.4M | $123.4M | $140.4M | $169.8M | $98.1M |
| Total debt | $603.4M | $540.0M | $414.9M | $2.9B | $350.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 23, 2026 | Sep 23, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 23, 2026 | Jun 22, 2026 |
All 502 Quidelortho Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.